Among the AML patients with DNMT3A mutations, 6.1% of patients had concomitant NPM1, FLT3‐ITD and IDH mutations while 24.2% AML patients had triple mutations of DNMT3A, NPM1 and FLT3‐ITD. This evidence concerns the gene DNMT3A and acute myeloid leukemia.